Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers

Antonio Tursi,Walter Elisei,R. Faggiani,Leonardo Allegretta,Nicola Della Valle,Giacomo Forti,Marilisa Franceschi,A. Ferronato,Sara Gallina,Tiziana Larussa,Francesco Luzza,Roberto Lorenzetti,G. Mocci,Antonio Penna,S. Rodiño,Ladislava Sebkova,Antonio de Medici,G. Pranzo,C. Ricciardelli,Giuseppina Grasso,Stefano Scorza,C. Zampaletta,Marcello Picchio

Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers

2018

AbstractAdalimumab (ADA) was approved in Italy for the treatment of ulcerative colitis (UC) unresponsive to standard treatments in 2014, but no data from real life are currently available. The aim of the present study was to assess the real-life efficacy and safety of ADA in managing UC outpatients

Keywords:

Medicine
Observational study
Physical therapy
Ulcerative colitis
Adalimumab
Inflammatory bowel disease
Diabetes mellitus
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations